CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease-Reference-Cited by-同舟云学术

CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease

Published:2020-09 Issue: Volume:18 Page:504-524
ISSN:2372-7705
Container-title:Molecular Therapy - Oncolytics
language:en
Short-container-title:Molecular Therapy - Oncolytics

Author:

Slabik Constanze,Kalbarczyk Maja,Danisch Simon,Zeidler Reinhard,Klawonn Frank,Volk Valery,Krönke Nicole,Feuerhake Friedrich,Ferreira de Figueiredo Constanca,Blasczyk Rainer,Olbrich Henning,Theobald Sebastian J.,Schneider Andreas,Ganser Arnold,von Kaisenberg Constantin,Lienenklaus Stefan,Bleich Andre,Hammerschmidt Wolfgang,Stripecke Renata

Funder

Deutsches Zentrum für Infektionsforschung

Publisher

Elsevier BV

Subject

Pharmacology (medical),Cancer Research,Oncology,Molecular Medicine

Reference61 articles.

1. How I treat EBV lymphoproliferation;Heslop;Blood,2009

2. Management of post-transplant lymphoproliferative disorders;DeStefano;Br. J. Haematol.,2018

3. Primary Epstein-Barr virus infection with and without infectious mononucleosis;Rostgaard;PLoS ONE,2019

4. Latency and lytic replication in Epstein-Barr virus-associated oncogenesis;Münz;Nat. Rev. Microbiol.,2019

5. Epigenetic lifestyle of Epstein-Barr virus;Buschle;Semin. Immunopathol.,2020

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma;Chinese Medical Journal;2024-08-23

2. Efficacy of NKG2D CAR-T cells with IL-15/IL-15Rα signaling for treating Epstein-Barr virus-associated lymphoproliferative disorder;Experimental Hematology & Oncology;2024-08-19

3. Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies;Biomarker Research;2024-07-29

4. EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-07-03

5. Treatment of Epstein-Barr Virus infection in immunocompromised patients;Biochemical Pharmacology;2024-07